Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Stock Information for Acasti Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acasti Pharma Inc.

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Outlook Therapeutics Provides Update on Type A Meeting with FDA
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
Outlook Therapeutics Requests Type A Meeting with FDA
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.